News

Researchers have reported the case of two men who were initially misdiagnosed with a rare type of hereditary angioedema (HAE) known as HAE-nC1INH-UNK when the correct diagnosis was the more common mast cell-mediated angioedema. This “exceedingly rare subtype of HAE … appears to be often diagnosed in patients who…

Rates of prescriptions for Firazyr (icatibant), an on-demand treatment to control swelling episodes in people with hereditary angioedema (HAE), have increased in recent years, especially for women, according to a study from Sweden. While the finding could mean that more patients have poorly-controlled disease, more prescriptions for the…

A single dose of Berinert, a concentrate of C1 esterase inhibitor, when given with standard treatment, may not do more to ease angioedema airway symptoms triggered by a type of medication called an angiotensin-converting enzyme (ACE) inhibitor, a study found. The study, “Efficacy of human C1 esterase…

A single injection of STAR-0215, an experimental treatment to prevent swelling attacks in people with hereditary angioedema (HAE), safely led to rapid and sustained inhibition of the kallikrein protein in healthy adults, according to preliminary data from a Phase 1a trial. “STAR-0215 has shown early proof of concept for…

PHVS416, an investigational oral therapy being developed by Pharvaris, was shown to be safe and effective in treating swelling attacks in patients with hereditary angioedema (HAE). The therapy substantially reduced symptoms, particularly skin swelling, skin pain, and abdominal pain. It also significantly shortened how…

A 64-year-old woman in Japan was diagnosed with hereditary angioedema (HAE) type 1 after being hospitalized with severe recurrent epigastric pain — pain in the upper abdomen, in the area below the ribs. Researchers said this case highlights the need to…

Xolair (omalizumab), an approved therapy for allergic asthma and chronic spontaneous urticaria (CSU), shows promise for treating idiopathic angioedema, according to data from a small Phase 4 trial. In the study, treatment for roughly six months with Xolair as an add-on therapy lessened disease activity when compared to…

Takhzyro (lanadelumab), an under-the skin injection therapy to prevent attacks in people with hereditary angioedema (HAE), has won the 2022 Prix Galien Canada Innovative Product Award. The prestigious annual award is given to a company — here, Takeda Pharmaceuticals — in recognition of a marketed product that has “made the most…

Adult and adolescent patients, ages 12 and older, with hereditary angioedema (HAE)  in Israel can now receive once-daily Orladeyo (berotralstat) to prevent HAE-related swelling attacks. The decision to approve the medication by the Israeli Ministry of Health follows similar decisions in Canada and Switzerland, as well as…

Donidalorsen, a small molecule therapy being developed by Ionis Pharmaceuticals, continues to be safe and to prevent swelling attacks when taken for up to one year by people with hereditary angioedema (HAE), trial data show. The open-label extension study (NCT04307381) is ongoing in patients who completed a placebo-controlled…